ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SCLP Scancell Holdings Plc

9.25
0.33 (3.70%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.33 3.70% 9.25 9.00 9.50 9.30 9.25 9.30 180,216 09:12:40
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -7.17 85.82M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 8.92p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £85.82 million. Scancell has a price to earnings ratio (PE ratio) of -7.17.

Scancell Share Discussion Threads

Showing 19751 to 19772 of 66275 messages
Chat Pages: Latest  791  790  789  788  787  786  785  784  783  782  781  780  Older
DateSubjectAuthorDiscuss
18/2/2019
08:28
I remember seeing BB comments that Modi will function without CI ?
What are you getting at ? Thanks.

torquayfan
18/2/2019
08:15
TF - yes it is and it was a genuine and important question.
bermudashorts
18/2/2019
08:11
Bermuda - I'm just glad to see THE man enthusing about vaccines.
I thought it was a very interesting link.

torquayfan
18/2/2019
07:44
TF

Thanks for that - so are we now suggesting that Moditope will also be a combination therapy?

bermudashorts
17/2/2019
16:37
Come on now, don't be shy, say what you mean!
10acious
17/2/2019
15:43
Don't forget the SCIB1 mouse model is proven ... LOL
inanaco
17/2/2019
15:21
10acious

Of course the field is so crowded because the rewards are so high. In the interest of balance this is from Scancell:-

'results demonstrate that it might be possible to rescue a poor vaccine and/or a non-responsive anti-PD-1 tumor by using a combination but then the survival is still very low. In contrast, our vaccine alone gives good survival and anti-PD-1 alone shows therapeutic efficacy in 50% of the animals (similar to results in melanoma patients) but the combination gives an overall survival of 80%.'

bermudashorts
17/2/2019
14:10
Thank you for that, very much an eye opener for me.What a crowded field,that has it seems,developed into nothing more than a dash for the cash. Easy now to see why progress for Scancell appears to be so slow.With the competition so vast the resources so relatively limited and failure rates as high as they are I'm happy to leave this in the... small speculative punt...bottom draw!As David Berman, who runs immuno-oncology at AstraZeneca, puts it bluntly: "Everything works in mice." And while animal models have improved in recent years, "they aren't as helpful as they were in other types of therapy-and even there, it's questionable how much predictiveness they have," adds Joanne Lager, who leads oncology development at Sanofi.Liked that bit of reality.
10acious
17/2/2019
12:00
Why is the market cap a whopping 24m?
kreature
17/2/2019
11:38
10acious thanks for that - below is link to an article posted a few months ago now. It's the best article on combination studies that I've read - not too detailed or technical and gives a good basic outline of the issues. It's a long article but would strongly recommend that any holders here have a read.

Re. your comment on patient nos. the article only includes figures up to 2017 but during the last 18 months there has been an explosion in the number of combination studies - depending on what article you read there are now between 1500 and 2500 trials. According to the Cancer Research Institute the figure is 2250 which involves the need to recruit over 380,000 patients. In some cancers there simply aren't enough patients to fill the trials.

The fact that Scancell have signed up major cancer centres in the US for the SCIB1 trial should very much help with recruitment for SCIB1 (assuming there's no change from previous announcements). When it comes to SCIB2, CRUK have a network of dedicated clinical trial centres.

bermudashorts
17/2/2019
09:27
Scancell have attended more meetings and presentations than Donald Trump.

It makes no difference to a positive outlook, indeed, it has a negative impact on the share price because they continue to burn money without income.

They have lost their way

terror
17/2/2019
08:28
Immunotherapies could change kidney cancer care, studies suggesthttps://www.cnn.com/2019/02/16/health/kidney-cancer-immunotherapies-combination-drug-study/index.htmlNot directly related but I found the numbers involved in the trial interesting....
10acious
16/2/2019
13:14
Dr - yes exactly, it's an investment conference so assume CH will be attending. Let's hope he needs to update his pitch with some progress on both platforms.
bermudashorts
16/2/2019
12:00
Looks like Scancell are attending Biotrinity in London in April.
bermudashorts
16/2/2019
02:12
Gazza. Thanks for the reply. Nice weekend to you.
torquayfan
15/2/2019
15:48
19797 -
So YOU call this LOSS making EGO trip of YOURs....LIFE do YOU ???
Sane people might call it = ' An Affliction'

the real lozan
15/2/2019
15:10
Tosh yet again decapitated ... life goes on for the rest of us
inanaco
15/2/2019
14:39
except the

SCIB1 tests results did transfer from mouse to Human ...

oh dear !!

inanaco
15/2/2019
14:29
Like i said, jog on... nothing you post is of any relevance .
anyone can cut and paste, and what your post has got to do with the fact that you've finally accepted that our " platforms " are NOT PROVEN, and do contain RISK, is a mystery.
Test results in mice do not always transfer to the same results in humans... FACT.

Now jog on theres a good lad.

tosh123
15/2/2019
14:18
Just so you know the difference between Jerry ...and a medical mouse as currently developed Tosh ..

A humanized mouse is a mouse carrying functioning human genes, cells, tissues, and/or organs. Humanized mice are commonly used as small animal models in biological and medical research for human therapeutics. Immunodeficient mice are often used as recipients for human cells or tissues, because they can relatively easily accept heterologous cells due to lack of host immunity. Traditionally, the nude mouse and severe combined immunodeficiency (SCID) mouse have been used for this purpose, but recently the NCG mouse, NOG mouse[1] and the NSG mouse[2] have been shown to engraft human cells and tissues more efficiently than other models.[3][4][5] Two mouse strains, called MITRG and MISTRG, were described in which human versions of four genes encoding cytokines important for innate immune cell development are knocked into their respective mouse loci. Such humanized mouse models may be used to model the human immune system in scenarios of health and pathology, and may enable evaluation of therapeutic candidates in an in vivo setting relevant to human physiology.[6]

search Wiki ...

for explanations of

Humanised Mouse

and you can form an argument with the industry rather than me

inanaco
15/2/2019
14:08
you are a tough guy ... i forgot !
inanaco
15/2/2019
14:06
and i suggest that you jog on.
Nothing you have to say is of any relevance.

tosh123
Chat Pages: Latest  791  790  789  788  787  786  785  784  783  782  781  780  Older

Your Recent History

Delayed Upgrade Clock